Physician profile
Jianping Chen
NPI 1245229814
$1,157,069.14
in general payments reported to CMS, 2019-2025
26 companies · $300K in 2025
The $300K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $43K · 2021: $60K · 2022: $148K · 2023: $239K · 2024: $236K · 2025: $300K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $558K · Consulting Fee: $84K · Travel and Lodging: $57K · Food and Beverage: $39K · Honoraria: $38K · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $557,627.38 |
| Consulting Fee | $84,129.00 |
| Travel and Lodging | $56,654.64 |
| Food and Beverage | $38,845.24 |
| Honoraria | $37,775.00 |
| Education | $225.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $254,664.31 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $230,248.64 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179,802.60 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $152,437.93 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $110,590.19 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $80,933.41 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $47,309.78 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $30,799.69 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $23,291.74 | 2019-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $15,804.78 | 2022-2024 | Quviviq |
| Indivior INC. | $13,825.96 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $10,414.44 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $3,698.11 | 2019-2022 | |
| Lundbeck LLC | $1,906.46 | 2019-2025 | Rexulti, Abilify Maintena, Brintellix |
| Janssen Pharmaceuticals, INC | $215.32 | 2019-2025 | Spravato, Invega Sustenna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $188.38 | 2019-2020 | |
| Novo Nordisk INC | $125.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Eisai INC. | $121.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.67 | 2023 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.52 | 2019-2024 | Rexulti |
| Noven Therapeutics, LLC | $86.67 | 2021 | |
| Corium, LLC | $80.21 | 2023 | Azstarys |
| Neuronetics, INC. | $44.22 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jianping Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.